Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CGTX
stocks logo

CGTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.077
-54.41%
--
--
-0.063
-54.76%
--
--
-0.053
-51.52%
Estimates Revision
The market is revising No Change the revenue expectations for Cognition Therapeutics, Inc. (CGTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -32.57%.
EPS Estimates for FY2025
Revise Downward
down Image
-23.53%
In Past 3 Month
Stock Price
Go Down
down Image
-32.57%
In Past 3 Month
Wall Street analysts forecast CGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.760
sliders
Low
3.00
Averages
3.00
High
3.00
Current: 1.760
sliders
Low
3.00
Averages
3.00
High
3.00
B. Riley
B. Riley
Buy
maintain
$2 -> $3
2025-11-21
Reason
B. Riley
B. Riley
Price Target
$2 -> $3
2025-11-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Cognition Therapeutics to $3 from $2 and keeps a Buy rating on the shares. Cognition's Phase 2 START trial for early Alzheimer's has fully enrolled 540 patients, reinforcing momentum from prior positive Phase 2b results and rising investigator interest in oral zervimesine, the analyst tells investors in a research note. With an 18-month primary endpoint and allowance for combination therapy, the trial design offers meaningful de-risking ahead of a mid-to-late 2027 readout, the firm adds.
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$5 -> $3
2025-05-27
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$5 -> $3
2025-05-27
downgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Cognition Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm cites the anticipated equity dilution later this year to extend the company's operational runway for the target cut. Zervimesine appears applicable across multiple fronts, the analyst tells investors in a research note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$6 → $5
2025-03-24
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$6 → $5
2025-03-24
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$11 → $8
2025-03-21
Reason
Chardan Capital
Daniil Gataulin
Price Target
$11 → $8
2025-03-21
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$11
2025-02-26
Reason
Chardan Capital
Daniil Gataulin
Price Target
$11
2025-02-26
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$5 → $6
2024-12-19
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$5 → $6
2024-12-19
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cognition Therapeutics Inc (CGTX.O) is -6.75, compared to its 5-year average forward P/E of -2.69. For a more detailed relative valuation and DCF analysis to assess Cognition Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.69
Current PE
-6.75
Overvalued PE
-0.22
Undervalued PE
-5.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CGTX News & Events

Events Timeline

(ET)
2025-12-01
07:40:00
Cognition Therapeutics Plans Registrational Program for Zervimesine in Alzheimer's Disease
select
2025-11-13 (ET)
2025-11-13
07:38:20
Cognition Therapeutics finishes enrolling participants for Phase 2 trial of Zervimesine
select
2025-11-06 (ET)
2025-11-06
07:38:33
Cognition Therapeutics Announces Q3 Earnings Per Share of 6 Cents, Below Consensus Estimate of 9 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-26NASDAQ.COM
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO

  • Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.

  • SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.

  • Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.

  • Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.

[object Object]
Preview
6.0
11-19Benzinga
HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
9.0
11-13Newsfilter
Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease

  • Cognition Therapeutics' START Study Enrollment: Cognition Therapeutics has successfully enrolled 540 participants in its Phase 2 START Study, which evaluates the safety and efficacy of zervimesine (CT1812) for treating mild cognitive impairment and early Alzheimer's disease, with results expected after 18 months of treatment.

  • Collaboration and Support: The study is supported by an $81 million grant from the National Institute of Aging and conducted in partnership with the Alzheimer's Clinical Trials Consortium, highlighting the collaborative effort in Alzheimer's research.

  • Zervimesine's Unique Mechanism: Zervimesine is an investigational oral drug that targets neurodegenerative diseases by potentially interrupting the toxic effects of harmful proteins in the brain, offering a new treatment avenue for patients who do not respond to existing therapies.

  • Future Implications for Alzheimer's Treatment: The study aims to explore zervimesine's role in combination therapy for patients already receiving approved monoclonal antibody treatments, potentially expanding treatment options for a broader range of Alzheimer's patients.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cognition Therapeutics Inc (CGTX) stock price today?

The current price of CGTX is 1.76 USD — it has decreased -2.22 % in the last trading day.

arrow icon

What is Cognition Therapeutics Inc (CGTX)'s business?

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

arrow icon

What is the price predicton of CGTX Stock?

Wall Street analysts forecast CGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cognition Therapeutics Inc (CGTX)'s revenue for the last quarter?

Cognition Therapeutics Inc revenue for the last quarter amounts to -6.38M USD, decreased -55.92 % YoY.

arrow icon

What is Cognition Therapeutics Inc (CGTX)'s earnings per share (EPS) for the last quarter?

Cognition Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cognition Therapeutics Inc (CGTX)'s fundamentals?

The market is revising No Change the revenue expectations for Cognition Therapeutics, Inc. (CGTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -32.57%.
arrow icon

How many employees does Cognition Therapeutics Inc (CGTX). have?

Cognition Therapeutics Inc (CGTX) has 25 emplpoyees as of December 05 2025.

arrow icon

What is Cognition Therapeutics Inc (CGTX) market cap?

Today CGTX has the market capitalization of 155.36M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free